Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2022-08-26 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司独立董事关于第二届董事会第四次会议相关议案的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors regarding a specific report titled '2022 Half-Year Fundraising Deposit and Actual Use Special Report.' The document is dated August 25, 2022, and it explicitly states that the independent directors have reviewed and agree with the report's content. The document itself does not contain the full report or detailed financial data but rather an opinion on the report's compliance and accuracy. The document length is short (1155 characters), and it serves as an attestation or certification of the report rather than the report itself. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a formal statement related to regulatory compliance and disclosure but does not contain substantive financial data or the full report.
2022-08-26 Chinese
成都先导药物开发股份有限公司关于召开2022年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2022 half-year performance explanation meeting (业绩说明会) for Chengdu Lead Drug Development Co., Ltd. It provides the date, time, location, and participation instructions for the meeting, which is intended to discuss the company's 2022 half-year operating results and financial indicators. The document does not contain actual financial statements or substantive financial data but rather informs investors about the upcoming event where such information will be discussed. The document length is short (1536 characters), and it serves as a notice for an investor presentation or earnings call rather than the report itself. Therefore, the most appropriate classification is Investor Presentation (IP).
2022-08-26 Chinese
成都先导药物开发股份有限公司2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2022 年半年度报告" which translates to "2022 Semi-Annual Report." It covers the period from January 1, 2022, to June 30, 2022, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data such as revenue, net profit, cash flow, and financial indicators, as well as management discussion and analysis, business overview, risk factors, and other comprehensive information typical of an interim or quarterly report. The document is lengthy (15,000 characters) and contains substantive financial data and analysis, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-26 Chinese
成都先导药物开发股份有限公司2022年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by the company during the half-year period of 2022. It includes specifics on the amount of funds raised, their storage, usage, changes in investment projects, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and it provides detailed financial figures related to fundraising and fund usage. The document is titled as a "专项报告" (special report) on the half-year fundraising funds' deposit and actual usage situation, which aligns with a capital/financing update rather than a full annual or interim financial report. It is not an announcement of a report publication, nor is it a certification or a brief summary. The content focuses on fundraising and capital management activities, consistent with the Capital/Financing Update category (CAP).
2022-08-26 Chinese
成都先导药物开发股份有限公司关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Chengdu Lead Drug Development Co., Ltd. regarding the progress of its share repurchase program through centralized bidding transactions. It details the number of shares repurchased, prices, total funds used, and references previous announcements about the share buyback plan. The document does not contain financial statements or comprehensive financial data but reports on the ongoing share repurchase activity. This fits the definition of a 'Transaction in Own Shares' filing, which reports on the company's buyback of its own shares.
2022-08-01 Chinese
成都先导药物开发股份有限公司关于以集中竞价交易方式首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's first share repurchase through centralized bidding on the stock exchange. It details the number of shares repurchased, prices, total funds used, and references the board's approval of the repurchase plan. The content focuses on the company's buyback activity and compliance with regulatory rules. There are no financial statements or comprehensive financial data presented, nor is this a report or earnings release. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on share repurchase activities.
2022-07-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.